Relation between the degree of procedural anticoagulation and complications after coronary stent implantation

American Journal of Cardiology

Volumn 92, Issue 3, 2003, Pages 319-322

  Ashby, Dale T ^a   Dangas, George ^a   Aymong, Eve A ^a   Farkouh, Michael E ^a   Mehran, Roxana ^a   Lansky, Alexandra J ^a   Moses, Jeffery W ^a   Leon, Martin B ^a   Stone, Gregg W ^a  

^a CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; GLYCOPROTEIN IIB INHIBITOR; GLYCOPROTEIN IIIA INHIBITOR; HEPARIN; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ADULT; AGED; ANGIOGRAPHY; ANTICOAGULATION; ARTICLE; BLEEDING DISORDER; CONTROLLED STUDY; CORONARY STENT; DISEASE EXACERBATION; FEMALE; HEART INFARCTION; HEMATOMA; HUMAN; KIDNEY FAILURE; LIMB ISCHEMIA; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0041345791     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(03)00637-4     Document Type: Article

References (16)

1. McGarry T.F. Jr, Gottlieb R.S., Morganroth J., Zelenkofske S.L., Kasparian H., Duca P.R., Lester R.M., Kreulen T.H. The relationship of anticoagulation level and complications after successful percutaneous transluminal coronary angioplasty. Am Heart J. 123:1992;1445-1451.
2. Ferguson J.J., Dougherty K.G., Gaos C.M., Bush H.S., Marsh K.C., Leachman D.R. Relation between procedural activated coagulation time and outcome after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol. 23:1994;1061-1065.
3. Narins C.R., Hillegass W.B. Jr, Nelson C.L., Tcheng J.E., Harrington R.A., Phillips H.R., Stack R.S., Califf R.M. Relation between activated clotting time during angioplasty and abrupt closure. Circulation. 93:1996;667-671.
4. Vainer J., Fleisch M., Gunnes P., Ramamurthy S., Garachemani A., Kaufmann U.P., Meyer B.J., Luscher T.F., Meier B. Low-dose heparin for routine coronary angioplasty and stenting. Am J Cardiol. 78:1996;964-966.
5. Boccara A., Benamer H., Juliard J.M., Aubry P., Goy P., Himbert D., Karrillon G.J., Steg P.G. A randomized trial of a fixed high dose vs a weight-adjusted low dose of intravenous heparin during coronary angioplasty. Eur Heart J. 18:1997;631-635.
6. Chesebro J.H., Rauch U., Fuster V., Badimon J.J. Pathogenesis of thrombosis in coronary artery disease. Haemostasis. 27:(suppl 1):1997;12-18.
7. D'Agostino R.B. Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Statistics Med. 17:1998;2265-2281.
8. Dangas G., Mintz G.S., Mehran R., Lansky A.J., Kornowski R., Pichard A.D., Satler L.F., Kent K.M., Stone G.S., Leon M.B. Preintervention arterial remodeling as an independent predictor of target-lesion revascularization after nonstent coronary intervention an analysis of 777 lesions with intravascular ultrasound imaging . Circulation. 99:1999;3149-3154.
9. Mehran R., Dangas G., Mintz G.S., Lansky A.J., Pichard A.D., Satler L.F., Kent K.M., Stone G.W., Leon M.B. Atherosclerotic plaque burden and CK-MB enzyme elevation after coronary interventions intravascular ultrasound study of 2256 patients . Circulation. 10:2000;604-610.
10. Rao A.K., Pratt C., Berke A., Jaffe A., Ockene I., Schreiber T.L., Bell W.R., Knatterud G., Robertson T.L., Terrin M.L. Thrombolysis in Myocardial Infarction (TIMI) Trial - phase I. Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol. 11:1988;1-11.
11. Chew D.P., Bhatt D.L., Lincoff A.M., Moliterno D.J., Brener S.J., Wolski K.E., Topol E.J. Defining the optimal activated clotting time during percutaneous coronary intervention aggregate results from 6 randomized, controlled trials . Circulation. 103:2001;961-966.
12. Xiao Z., Theroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation. 97:1998;251-256.
13. Knight C.J., Panesar M., Wilson D.J., Patrineli A., Chronos N., Wright C., Clarke D., Patel D., Fox K., Goodall A.H. Increased platelet responsiveness following coronary stenting. Heparin as a possible etiological factor in stent thrombosis. Eur Heart J. 19:1998;1239-1248.
14. Mascelli M.A., Kleiman N.S., Marciniak S.J. Jr, Damaraju L., Weisman H.F., Jordan R.E. Therapeutic heparin concentrations augment platelet reactivity implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab . Am Heart J. 139:2000;696-703.
15. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 336:1997;1689-1696.
16. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT) a randomised, placebo-controlled trial . Lancet. 356:2000;2037-2044.